News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
13-Dec-2005 - Dyax Corp. announced several key management promotions. Thomas R. Beck, M.D. has been promoted to President and Chief Operating Officer, Clive Wood, Ph.D. has been promoted to Executive Vice President, Discovery Research and Chief Scientific Officer and Ivana Magovcevic-Liebisch, Ph.D., J.D. has ...
12-Dec-2005 - Dyax Corp. and Genzyme Corporation announced that patient treatment has begun in their pivotal Phase III clinical trial of Dyax's recombinant plasma kallikrein inhibitor known as DX-88. In this trial, referred to as EDEMA3, DX-88 is being studied for the treatment of patients with hereditary ...
Positive Experience with Subcutaneously Administered DX-88 in the Ongoing, Phase II Open-Label EDEMA2 Trial for Hereditary Angioedema
09-Nov-2005 - Dyax Corp. announced positive final data from its completed Phase I trial, demonstrating that DX-88 was safe and well tolerated in normal volunteers when administered subcutaneously. Dr. Thomas R. Beck, Executive Vice President, Business and Product Development of Dyax, also reported positive ...
26-Jan-2005 - Dyax Corp. announced that Anthony H. Williams, FCRP, Senior Vice President of Medical Affairs and Clinical Operations, has resigned from Dyax in order to accept a senior clinical oncology position with a major pharmaceutical company. Dr. Williams will remain available to Dyax as a consultant ...
30-Nov-2004 - Dyax Corp. has granted a non-exclusive license to its proprietary antibody phage display libraries to Tanox, Inc. Tanox, which specializes in the development of biotherapeutics for asthma, allergy, oncology, inflammation and infectious disease, intends to utilize the Dyax libraries to identify ...
23-Nov-2004 - Dyax Corp. announced a collaboration with EPIX Pharmaceuticals, Inc. for the discovery and development of peptides to be used as imaging agents and/or therapeutics. Under the terms of the agreement, the companies will conduct a research program utilizing Dyax's proprietary phage display ...
11-Nov-2004 - Dyax Corp. today announced a research collaboration to provide Biogen Idec with access to Dyax's fully human antibody libraries for the purpose of identification and characterization of therapeutic and/or diagnostic antibodies against up to thirty Biogen Idec protein targets per year. Under the ...
03-Jun-2004 - Cambridge, Mass. - Dyax Corp announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to Genzyme Corporation for the discovery of human antibodies, initially for use in the research field and with options for therapeutic antibody product ...
13-Jan-2004 - CAMBRIDGE, Mass., -- Dyax Corp. announced a research collaboration with Baxter Healthcare Corporation to utilize Dyax's proprietary phage display technology to discover antibodies that block macrophage migration inhibitory factor (MIF), a clinical target to which Baxter has an exclusive license ...
15-Aug-2003 - Affimed Therapeutics AG and Dyax Corp. announced today that they have entered into a cross-licensing agreement for phage display technologies. Financial terms were not disclosed. The Affimed licensed patents consist of two issued U.S. patents with broad claims. They cover the generation of human ...
© 1997-2024 LUMITOS AG, All rights reserved